Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Final Survival Outcomes of the Randomized Phase 3 PRODIGY Trial - Neoadjuvant Docetaxel, Oxaliplatin, & S-1 + Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer"

121 views
July 11, 2023
Comments 0
Login to view comments. Click here to Login